Appointment of Joint Broker

Vectura Group plc

Appointment of Joint Broker

Chippenham, UK - 23 December 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, today announces the appointment of Numis Securities Ltd as the Company's joint corporate broker alongside J.P. Morgan Cazenove, with immediate effect.

- Ends -

Enquiries

Vectura Group plc +44 (0) 1249 667700

Andrew Derodra - Chief Financial Officer

Fleur Wood - Director Communications

Elizabeth Knowles - Director Investor Relations and Analysis

J.P. Morgan Cazenove +44 (0) 207 742 4000

James Mitford

Alex Bruce

Chris Cargill

Numis Securities Ltd

Clare Terlouw +44 (0) 207 260 1000

Freddie Barnfield

James Black

Consilium Strategic Communications [email protected]

Mary-Jane Elliott / Sue Stuart / Jessica Hodgson

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.